In addition, it will be important to validate (analytically and clinically) other ctDNA-based predictive biomarkers/companion diagnostics, especially RAS mutation testing for predicting resistance to anti-EGFR antibodies in patients with CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.